ABSTRACT: Examples of organometallic compounds as nucleoside analogues are rare within the field of medicinal bioorganometallic chemistry. We report on the synthesis and properties of two chiral ferrocene derivatives containing both a nucleobase and a hydroxyalkyl group. These so-called ferronucleosides show promising anticancer activity, with cytostatic studies on five different cancer cell lines indicating that both functional groups are required for optimal activity.
Nucleoside analogues have long been established as an effective class of compound that exhibits antiviral or anticancer activity.
1 Two common structural features are a nucleobase moiety and a hydroxylmethyl group (Figure 1) , which together allow them to act as substrates that adversely affect processes associated with nucleic acid synthesis. These two components are typically connected by an organic linker group that is a modification or a replacement of the sugar ring, which can either be cyclic (e.g. AZT) or acyclic (e.g. acyclovir).
2 Due to their structural similarities to natural nucleosides, which can lead to resistance and side-effects, there is a continuing need for a diverse range of analogues with different structural features. Ferrocene has attracted active interest in recent years within the field of medicinal and bioorganometallic chemistry, 3 with organometallic analogues and derivatives of the antimalarial drug chloroquine (ferroquine) and the breast cancer drug tamoxifen (the ferrocifen family) being the most widely known. 4 At the same time there has been a number of examples of other ferrocene containing compounds that have shown anticancer, 5 antibacterial and antifungal properties. 6 However although there are also some recent examples of ferrocene-conjugated nucleobases 7 and hydroxylalkyl ferrocenes 8 that exhibit anticancer activity, as far as we are aware, nucleoside analogues of the type shown in Figure 1 that are bridged solely by an organometallic linker group and show biological activity have not been reported. 9 As part of our programme to develop novel metal-containing analogues of DNA and its components, 10 we recently reported an organometallic nucleic acid oligomer designated as Ferrocene Nucleic Acid (FcNA). 10b The monomeric components of the reported form of FcNA consist of a tetra-substituted ferrocene unit containing two alkyl hydroxyl groups to allow connectivity via phosphodiesters, and two thymine nucleobases. We noticed that these monomeric compounds have the required features for a novel nucleoside analogue, where the 5-membered sugar ring is substituted for a 5-membered cyclopentadienyl ring of a ferrocene unit. Accordingly we now report bis-substituted ferrocenes 1 and 2 (so-called ferronucleosides), that contain both a nucleobase (thymine or adenine) and a hydroxyl group, along with various control compounds (Fig. 2) . The cell line studies reported here demonstrate the promise of these ferrocenyl derivatives as a novel class of nucleoside analogue that show anticancer activity. It was decided to first synthesize nucleoside analogues with a 1,2-disubstituted arrangement on one Cp ring, with the other Cp ring unfunctionalized. This would enable us to utilize the synthetic chemistry already developed within the group for FcNA monomer synthesis.
10b For the same reason, the compounds would have a three-carbon hydroxyl linker (with a methyl group on the alpha carbon to direct ortholithiation) and a two-carbon linker to the nucleobase. The synthetic route taken to make the ferronucleoside targets 1 and 2 is outlined in Scheme 1. The chirally pure Ugi amine 11 7 was treated with n-BuLi and quenched with iodine to introduce the required planar 1,2-disubstitution pattern. Subsequent functional group inter-conversion gave compound 11, to provide the chain extension giving a three carbon linker. Treatment of 11 with silyl enol ether, catalysized by the Lewis acid boron trifluoride, gave compound 12 in good yield. Reduction of the ester, followed by TBDPS protection gave compound 14. Conversion to aldehyde 15 (via n-BuLi halogen exchange and quenching with DMF) enabled a Wittig reaction to be performed to from alkene 16, with subsequent hydroboration-oxidation giving the mono-protected bis-alcohol 17 in high chiral purity (as checked by chiral HPLC analysis, overall 97% ee). The conversion of 17 to the target compounds 1 and 2 proceeded via a Mitsunobu reaction with the appropriate protected nucleobase, followed by deprotection of the protecting groups. The family of compounds was also extended by making the control compounds 3-6 (Fig. 2) , to assess the role of the alcohol and nucleobase groups, noting that compound 6 had previously been shown 8 to display antineoplastic activity against cervix carcinoma (HeLa) tumor cells.
The cytostatic activity of six ferrocene compounds was evaluated in comparison to the established anticancer drugs cisplatin and 5-fluorouracil (5-FU) using a proliferation activity assay carried out on three tumor cell lines: murine leukemia cells (L1210), HeLa, and human T-lymphocyte cells (CEM). The data indicate that the concomitant presence of both the hydroxyl and nucleobase components are of crucial importance to give the highest cytostatic activity, with 1 and 2 exhibiting low to sub micromolar antiproliferative activity comparable with cisplatin (Table 1 ). In addition, 1 and 2 were almost equally as active as 5-FU in L1210 cell cultures, 2-to 5-fold less active in HeLa cell cultures, but 20-to 50-fold more active in CEM cell cultures. Compounds 1 and 2 proved poorly toxic to non-tumorigenic human embryonic lung (HEL) fibroblast cell cultures (minimal cytotoxic concentration: >50 µM). Cell growth studies carried out on an oesophageal cancer cell line revealed that compound 1 inhibited growth at concentrations of 6.25 µM, whereas control compounds 3 and 4 ( Figure 3 and supplementary data respectively) had much less or no effect, even up to higher concentrations of 25 µM. The same trend was observed for the adenine compound 2 and its control 5 (see supplementary data). Once again the data indicates that both functional groups (the hydroxyl in addition to the nucleobase) are required for the best cytostatic activities, which is comparable to cisplatin under these conditions. Assays of cellular viability (MTT assay) and cell proliferation (BrdU assay) were then performed on colorectal cancer cell lines. The results after 48hr exposure (Figure 4 ) revealed that compounds 1 and 2 had anti-neoplastic activities approaching that 5-FU, whereas the other compounds were less effective. Encouragingly, an AMES assay to investigate the potential mutagenicity of these ferrocenyl derivatives revealed that the compounds were inactive. In conclusion, novel ferrocenyl nucleoside analogues 1 and 2 appear to exhibit cytostatic activities that are comparable under the conditions used to commercially established anticancer drugs such as cisplatin and 5-FU. Control studies indicate that the presence of both a hydroxyl and a nucleobase group are required for optimal activity. This suggests a mechanistic role for these novel bioorganometallic compounds involving an adverse affect on nucleic acid synthesis, as is the case for nucleobase analogue drugs containing organic linker groups. 12 We are currently planning to carry out further studies to reveal the mode of action of these ferronucleosides and to highlight stereochemical and structure activity relationships for improving biological activity and specificity.
EXPERIMENTAL SECTION General Information: Unless stated otherwise, all reactions were performed under an Ar atmosphere. Compound 6 was prepared as described previously. 8 All tested compounds had a purity of ≥95%, as shown by HPLC (see supplementary information for data and conditions used).
(R,Sp)-1-(α-N,N-Dimethylaminoethyl)-2-iodo-ferrocene (8). The Ugi amine 7 11 (4.00 g, 15.56 mmol) was dissolved in Et2O (50 ml) at room temperature, n-BuLi (12 ml, 30 mmol) was added and the mixture stirred overnight. The reaction mixture was cooled to -78°C and iodine (9.52 g, 37.51 mmol), dissolved in THF (60 ml), was added over 10 min. The reaction mixture was stirred at -78°C for 90 min before being warmed to room temperature, at which point it was stirred for an additional 90 min before being quenched at 0°C with sodium thiosulfate(aq) (50 ml, 25% w/v). After dilution with Et2O (30 ml), the layers were separated and the aqueous layer further extracted with Et2O (3 x 50 ml). The combined organic fractions were dried over MgSO4, the solvent removed in vacuo before purification via flash column chromatography (5% MeOH, 5% TEA in DCM) to yield product (3.18 g, 55%). (R,Sp)-1-(α-Acetoxyethyl)-2-iodo-ferrocene (9). Compound 8 (3.26 g, 8.51 mmol) and acetic anhydride (25.68 ml, 272.17 mmol) were heated at 50°C for 2 hrs. The acetic anhydride was removed under high vacuum (0.1 mmHg) and the residue purified via flash column chromatography (10% EtOAc in hexane) to yield the yellow-brown oily product (2.94 g, 87%). (35 ml). NaOH(aq) (30 ml, 10% w/v) was added and the reaction was heated at 95°C for 15 min. After cooling to room temperature, the organic layer was extracted with EtOAc (2 x 40 ml). The organic layers were dried over Na2SO4, the solvent removed in vacuo and the residue purified via flash column chromatography (25% EtOAc in hexane) to yield the yellow oily product (2.43 g, 92%)
1 H NMR (400 MHz, CDCl3) δ 4.85 (qd, J = 6.5, 2.8 Hz, 1H), 4.46 (dd, J = 2.5, 1.4 Hz, 1H), 4.29 (dd, J = 2.7, 1.3 Hz, 1H), 4.25 (t, J = 2.6 Hz, 1H), 4.14 (s, 5H), 1.88 (d, J = 3.6 Hz, 1H), 1.62 (d, J = 6.5 Hz, 3H). (R,Sp)-1-(α-Methoxyethyl)-2-iodo-ferrocene (11). Compound 10 (2.43 g, 6.83 mmol) was dissolved in a MeOH/AcOH (20 ml, 9:1) mixture and the solution was stirred at room temperature for 48 hrs. The reaction was quenched with water (10 ml) and extracted with DCM (2×20 ml). The combined organic fractions were dried over MgSO4, the solvent removed in vacuo and the residue purified via flash column chromatography (25% EtOAc in hexane) to yield the yellow oily product (2.37 g, 94%). .42 mmol) and 1-ethoxyvinyloxytrimethylsilane (8.234 g, 51.37 mmol) were dissolved in DCM (30 ml). The mixture was cooled to -78°C and BF3.OEt2 (1.77 ml, 14.12 mmol) was then added dropwise. The reaction mixture was stirred for 15 min at -78°C before being warmed to room temperature and quenched with saturated NaHCO3 (40 ml). The organic layer was separated and the aqueous layer was further extracted with DCM (40 ml). The combined organic fractions were dried over MgSO4, the solvent removed in vacuo and the residue purified via flash column chromatography (10% EtOAc in hexane) to yield the yellow oily product (1.676 g, 61%). Compound 12 (1.592 g, 3 .73 mmol) was dissolved in Et2O (50 ml) and the solution was cooled to 0°C. After standing for 5 min, diisobutylalumminum hydride (11.2 ml, 11.2 mmol) was added slowly at that temperature. The mixture was stirred at 0°C for 1 hr before the reaction was quenched with saturated sodium potassium tartrate in water (30 ml). The layers were separated and the aqueous layer was further extracted with Et2O (30 ml). The combined organic fractions were dried over Na2SO4, the solvent removed in vacuo and the residue purified via flash column chromatography (50% EtOAc in hexane) to yield the product (1.413 g, 99%).
1 H NMR (400 MHz, CDCl3) δ 4.42 (dd, J = 2.4, 1.4 Hz, 1H), 4.17 (td, J = 2.6, 0.6 Hz, 1H), 4.13 (s, 5H), 4.06 (dd, J = 2.7, 1.3 Hz, 1H), 3.59 (t, J = 6.6 Hz, 2H), 2.78 -2.69 (m, 1H), 1.72 -1.52 (m, 2H), 1.41 (d, J = 7.0 Hz, 3H). 13 (
S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-iodo-ferrocene (14). Compound 13
(1.413 g, 3.67 mmol) was dissolved in DCM (20 mL) at room temperature. TEA (0.77 ml, 5.52 mmol), tert-butyldiphenylsilyl chloride (1.44 ml, 5.51 mmol) and DMAP (catalytic amount) were added to the mixture. The solution was then stirred overnight at room temperature before quenching with water (10 ml). The phases were separated and the aqueous layer was extracted with Et2O (2 x 20 ml). The combined organic fractions were dried over Na2SO4, the solvent removed in vacuo and the residue purified via flash column chromatography (10% EtOAc in hexane) to yield a yellow oily product (2 g, 95% (
S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-formyl-ferrocene (15). Compound 14
(2.182 g, 3.51 mmol) was dissolved in Et2O (30 ml), the mixture was cooled to -78°C and n-BuLi (2.32 ml, 7.01 mmol) was added. After 30 min, DMF (0.68 ml, 8.76 mmol) was added and the mixture was stirred at -78°C for another 30 min before being allowed to warm to room temperature before quenching with water (20 ml). The phases were separated and the aqueous layer was extracted with Et2O (2 x 20 ml). The combined ethereal fractions were dried over Na2SO4, the solvent removed in vacuo and the residue purified via flash column chromatography (10% EtOAc in hexane) to yield the red oily product (1.686 g, 92%). , 1H), 4.43 (dd, J = 2.6, 1.4 Hz, 1H), 4.21 (s, 5H), 3.61  (t, J = 7.1, 2H), 3.21 -3.10 (m, 1H), 1.73 -1.50 (m, 2H),  1.34 (d, J = 6.9 Hz, 3H), 1.04 (s, 9H) . 13 82 mmol) and a catalytic amount of dibenzo-18-crown-6-ether were dissolved in THF (20 ml). The mixture was stirred for 30 min and then 15 (1.686 g, 3.21 mmol), dissolved in THF (30 ml), was added to the mixture. The reaction mixture was stirred overnight at room temperature, before quenching with water (10 ml) and extracting with Et2O (2 x 20 ml). The combined ethereal fractions were dried over Na2SO4, solvent removed in vacuo and purified via flash column chromatography (5% EtOAc in hexane) to yield the product as a yellow oil (1.497 g, 89%). (
S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-[2-(hydroxyl)ethyl]-ferrocene (17).
Compound 16 (1.497 g, 2.87 mmol) was dissolved in THF (30 ml). BH3.THF (1M, 8.2 ml, 8.2 mmol) was then added dropwise at room temperature and the mixture stirred for 2 hrs. EtOH (9.76 ml), NaOH (3M, 9.76 ml, 29.28 moles) and H2O2 (30 wt. % in water, 7.17 ml, 63.24 moles) were then successively added and the mixture stirred for 1 hr at room temperature. The reaction mixture was extracted with DCM (30 ml), washed with brine (20 ml) and then dried over Na2SO4. The solvent was removed in vacuo and the residue purified via flash column chromatography (10% EtOAc in hexane) to yield the yellow oily product (1.434 g, 82%). , 3H), 1.06 (s, 9H) . 13 ]-ferrocene (1) . Triphenylphosphine (137 mg, 0.516 mmol), 3-benzoyl thymine 13 (95 mg, 0.447 mmol) and compound 17 (0.186 g, 0.344 mmol) were dissolved in THF (10 ml) and stirred for 10 min at room temperature. The flask was then covered with foil and DIAD (0.11 ml, 0.516 mmol) was added at room temperature before the mixture was heated at 65°C for 2 hrs. The reaction mixture was evaporated, extracted with EtOAc (30 ml), washed with brine (20 ml) followed by water (20 ml) and dried over Na2SO4. The solvent was removed in vacuo and the residue purified via flash column chromatography (30% EtOAc in hexane) to give the fully protected product (219 mg, 85%). Deprotection was achieved firstly by stirring the compound in 5 ml of TBAF for 2 hr before the solvent was removed. The mixture was then redissolved in methylamine (33 wt. % in ethanol, 2 ml) and stirred at room temperature for an addition 30 min. The methylamine was evaporated and the crude was purified via flash column chromatography (5% MeOH in DCM) to give the product as a yellow oil (105 mg, 74%). 109 mmol) and compound 17 (0.300 g, 0.555 mmol) were dissolved in THF (10 ml) and stirred for 10 min at room temperature. The flask was then covered with foil and DIAD (0.24 ml, 1.109 mmol) was added at room temperature before the mixture was warmed up to 65°C for 2 hrs. The reaction mixture was evaporated, extracted with EtOAc (30 ml), washed with brine (20 ml) followed by water (20 ml) and dried over Na2SO4. The solvent was removed in vacuo and the residue purified via flash column chromatography (30% EtOAc in hexane) to give the protected product (0.343 g, 72%). Deprotection was achieved firstly by stirring the compound in TBAF (5 ml, 1M) for 2 hr. The solvent was then removed and the residue redissolved in methylamine (33 wt. % in ethanol, 2 ml) and stirred at room temperature for an additional 30 min. The methylamine was then evaporated and the crude mixture purified via flash column chromatography to give the product as a yellow solid (170 mg, 73% 15 (220 mg, 0.733 mmol) was dissolved in diethyl ether (10 ml). LiAlH4 (56 mg, 1.466 mmol) was added carefully and the resulting suspension was left to stir for 1 hr. The reaction was quenched with saturated sodium potassium tartrate (10 ml), extracted with diethyl ether (2 x 20ml), dried over MgSO4 and the solvent removed in vacuo. The residue was purified via flash column chromatography to give the product as a yellow oil (100 mg, 58% 1-(Thyminyl-)ethyl-ferrocene (4). Triphenylphosphine (348 mg, 1.30 mmol), N-3-benzoylthymine 13 (223 mg, 1.04 mmol), and 2-ferrocenylethanol 16 (200 mg, 0.87 mmol) were dissolved in THF (10 ml) and stirred for 10 min at room temperature. The flask was then covered with foil and DIAD (0.28 ml, 1.30 mmol) was added at room temperature before the mixture was heated at 65°C for 2 hrs. The solvent was then evaporated and the residue extracted with EtOAc (30 ml), washed with brine (20 ml) and water (20 ml) and dried over Na2SO4, before the solvent was removed in vacuo. Deprotection was achieved by treating the crude mixture with methylamine solution (33 wt. % in ethanol, 5 ml) for 30 min. The solvent was then evaporated in vacuo and the residue purified via flash column chromatography (40% EtOAc in hexane) to give the product (176 mg, 60%). ): 3146 (NH), 2999 (CH), 1683 (C=O), 1644 (NH bending).
1-[2-(Adenin-9-yl)ethyl]-ferrocene (5).
Triphenylphosphine (0.383 g, 1.46 mmol), N,N-6,6-dibenzoyladenine 14 (0.500 g, 1.46 mmol) and 2-ferrocenylethanol 16 (0.201 g, 0.73 mmol) were dissolved in THF (10 ml) and stirred for 10 min at room temperature. The flask was then covered with foil and DIAD (0.24 ml, 1.18 mmol) was added at room temperature before the mixture was warmed up to 65°C for 2 hrs. The reaction mixture was evaporated, extracted with EtOAc (30 ml), washed with brine (20 ml) followed by water (20 ml) and then dried over Na2SO4. The solvent was removed in vacuo and purified via flash column chromatography (40% EtOAc in hexane) to give the bis-protected product (0.134 g, 33%). Deprotection was achieved by dissolving the compound (0.055 g, 0.1 mmol) in methylamine (33 wt. % in ethanol, 3 ml) and stirring at room temperature for 30 min. The methylamine was then evaporated and the residue purified via flash column chromatography (95/5 DCM/MeOH) to give the product as a yellow solid (0.019 g, 58% 
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